New $38 million study tests if common drugs can extend healthy aging
一項耗資 3,800 萬美元的新研究旨在測試常見藥物是否能延緩衰老並促進健康。
A groundbreaking $38 million study called VITAL-H is challenging how we approach getting older.
一項名為VITAL-H，耗資3800萬美元的開創性研究，正在挑戰我們對於變老（ㄅㄧㄢˋㄌㄠˇ）的看法。
Led by the Barshop Institute at UT Health San Antonio, this clinical trial aims to move medicine beyond just treating diseases after they appear.
這項臨床試驗由德州大學聖安東尼奧分校健康科學中心的Barshop研究所領導，旨在將醫學的重點從疾病出現後的治療，轉向更前瞻性的作法。
Instead, the goal is to proactively improve 'healthspan'—the number of years we live in good health—by testing if existing, FDA-approved medications can slow down biological aging.
相反地，該研究的目標是透過測試現有且經FDA批准的藥物是否能減緩生物學上的老化，來主動改善「健康壽命」（我們維持健康狀態生活的年數）。
Funded by the Advanced Research Projects Agency for Health (ARPA-H), the study will follow 726 adults between 60 and 65.
在美國衛生高級研究計畫局（ARPA-H）的資助下，該研究將追蹤726名60至65歲的成年人。
Participants will be tested with three drugs: Rapamycin, Dapagliflozin, and Semaglutide.
參與者將接受三種藥物測試：雷帕黴素（Rapamycin）、達格列淨（Dapagliflozin）和司美格魯肽（Semaglutide）。
Historically, longevity research was limited to animal models, but this trial brings those concepts directly to humans.
過往的長壽研究僅限於動物模型，但這項試驗直接將這些概念應用於人類。
The ultimate ambition is to narrow the gap between our lifespan and our healthspan, ensuring that as we live longer, we also stay more independent and vibrant.
其最終的抱負是縮小壽命與健康壽命之間的差距，確保我們在活得更久的同時，也能保持更獨立且充滿活力的狀態。
By focusing on prevention rather than reaction, this project could transform modern healthcare, making healthy aging an accessible reality rather than an exclusive privilege for the few.
藉由專注於預防而非反應，該計畫可能徹底改變現代醫療保健，使健康老化成為普遍的現實，而非少數人的特權。
